He Jie Tang in the treatment of chronic hepatitis B patients

World Journal of Gastroenterology

Volumn 11, Issue 42, 2005, Pages 6638-6643

  Chen, Ze Xiong ^a   Zhang, Shi Jun ^a   Lao, Shao Xian ^b   Hu, Hong Tao ^a   Zhang, Cui Yig ^a   Guan, Shi He ^c   Gu, Yan Li ^c  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Chronic hepatitis B; Cytokines; He Jie Tang; Lymphocyte subsets; NK cell

Indexed keywords

ALANINE AMINOTRANSFERASE; ASCORBIC ACID; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BUPLEURUM ROOT; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHINESE DRUG; CODONOPSIS PILOSULA EXTRACT; CYTOKINE; ESTER; GLYCYRRHIZA EXTRACT; HE JIE TANG; HEDYOTIS DIFFUSA EXTRACT; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 8; MORINDA OFFICINALIS EXTRACT; OXYMATRINE; PINELLIA EXTRACT; PLANT EXTRACT; POLYGONUM CUSPIDATUM EXTRACT; SCUTELLARIAE RADIX; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS DNA; VITAMIN B GROUP; ZIZIPHUS JUJUBA EXTRACT;

ADULT; ARTICLE; CELL ACTIVITY; CELLULAR IMMUNITY; CHRONIC HEPATITIS; CLINICAL TRIAL; CODONOPSIS; CODONOPSIS PILOSULA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; GLYCYRRHIZA; HEDYOTIS; HEDYOTIS DIFFUSA; HEPATITIS B; HUMAN; HUMAN CELL; JUJUBE; MAJOR CLINICAL STUDY; MORINDA; MORINDA OFFICINALIS; NATURAL KILLER CELL; NONHUMAN; POLYGONUM CUSPIDATUM; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE SUBPOPULATION; ZIZIPHUS JUJUBA;

EID: 30444443640     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i42.6638     Document Type: Article

References (38)

1. Kagawa T, Watanabe N, Kanouda H, Takayama I, Shiba T, Kanai T, Kawazoe K, Takashimizu S, Kumaki N, Shimamura K, Matsuzaki S, Mine T. Fatal liver failure due to reactivation of lamivudine-resistant HBV mutant. World J Gastroenterol 2004; 10: 1686-1687
2. Ohata K, Hamasaki K, Toriyama K, Ishikawa H, Nakao K, Eguchi K. High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol 2004; 19: 670-675
3. Ikeda K, Kobayashi M, Saitoh S, Someya T, Hosaka T, Akuta N, Suzuki Y, Suzuki F, Tsubota A, Arase Y, Kumada H. Significance of hepatitis B virus DNA clearance and early prediction of hepatocellular carcinogenesis in patients with cirrhosis undergoing interferon therapy: long-term follow up of a pilot study. J Gastroenterol Hepatol 2005; 20: 95-102
4. Ikeda K, Arase Y, Kobayashi M, Someya T, Saitoh S, Suzuki Y, Suzuki F, Tsubota A, Akuta N, Kumada H. Consistently low hepatitis B virus DNA saves patients from hepatocellular carcinogenesis in HBV-related cirrhosis. A nested case-control study using 96 untreated patients. Intervirology 2003; 46: 96-104
5. Torre F, Cramp M, Owsianka A, Dornan E, Marsden H, Carman W, Williams R, Naoumov NV. Direct evidence that naturally occurring mutations within hepatitis B core epitope alter CD4+ T-cell reactivity. J Med Virol 2004; 72: 370-376
6. Mutimer D. Hepatitis B virus antiviral drug resistance: from the laboratory to the patient. Antivir Ther 1998; 3: 243-246
7. Jang MK, Chung YH, Choi MH, Kim JA, Ryu SH, Shin JW, Kim IS, Park NH, Lee HC, Lee YS, Suh DJ. Combination of alpha-interferon with lamivudine reduces viral breakthrough during long-term therapy. J Gastroenterol Hepatol 2004; 19: 1363-1368
8. Jang MK, Chung YH, Choi MH, Kim JA, Ryu SH, Shin JW, Kim IS, Park NH, Lee HC, Lee YS, Suh DJ. Combination of alpha-interferon with lamivudine reduces viral breakthrough during long-term therapy. J Gastroenterol Hepatol 2004; 19: 1363-1368
9. Mutimer D. Hepatitis B virus infection: resistance to antiviral agents. J Clin Virol 2001; 21: 239-242
10. Leung N. Treatment of chronic hepatitis B: case selection and duration of therapy. J Gastroenterol Hepatol 2002; 17: 409-414
11. Fischer KP, Gutfreund KS, Tyrrell DL. Lamivudine resistance in hepatitis B: mechanisms and clinical implications. Drug Resist Updat 2001; 4: 118-128
12. Fung SK, Lok AS. Treatment of chronic hepatitis B: who to treat, what to use, and for how long? Clin Gastroenterol Hepatol 2004; 2: 839-848
13. Schiefke I, Klecker C, Maier M, Oesen U, Etzrodt G, Tannapfel A, Liebert UG, Berr F. Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a. Liver Int 2004; 24: 98-104
14. Zhang SJ, Chen ZX, Huang BJ. Effect of hejie decoction on T-cell receptor V beta 7 gene expression in patients of chronic hepatitis B. Zhongguo Zhongxi Yijiehe Zazhi 2002; 22: 499-501
15. Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Brechot C, Michel ML. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 2004; 40: 874-882
16. Shimada N, Yamamoto K, Kuroda MJ, Terada R, Hakoda T, Shimomura H, Hata H, Nakayama E, Shiratori Y. HBcAg-specific CD8 T cells play an important role in virus suppression, and acute flare-up is associated with the expansion of activated memory T cells. J Clin Immunol 2003; 23: 223-232
17. Hasebe A, Akbar SM, Furukawa S, Horiike N, Onji M. Impaired functional capacities of liver dendritic cells from murine hepatitis B virus (HBV) carriers: relevance to low HBV-specific immune responses. Clin Exp Immunol 2005; 139: 35-42
18. Kondo Y, Kobayashi K, Asabe S, Shiina M, Niitsuma H, Ueno Y, Kobayashi T, Shimosegawa T. Vigorous response of cytotoxic T lymphocytes associated with systemic activation of CD8 T lymphocytes in fulminant hepatitis B. Liver Int 2004; 24: 561-567
19. Lee CK, Suh JH, Cho YS, Han KH, Chung JB, Chon CY, Moon YM. Direct analysis of HBV-specific CD8+ lymphocyte by tetrameric HLA-A2/ core 18-27 complex in chronic Hepatitis B. Taehan Kan Hakhoe Chi 2002; 8: 139-148
20. Xuan SY, Sun Y, Zhang J. The influence to the function of cellular immunity after being infected by HBV in the PBMC in chronic hepatitis B. Zhonghua Liuxing Bingxue Zazhi 1997; 18: 80-82
21. Ahn DS, Jang HC, Ahn JK, Yim CY, Kim DG. Impaired interleukin-2 receptor expression on lymphocytes from patients with chronic active hepatitis type B. Korean J Intern Med 1989; 4: 34-40
22. Dong Z, Wei H, Sun R, Hu Z, Gao B, Tian Z. Involvement of natural killer cells in PolyI: C-induced liver injury. J Hepatol 2004; 41: 966-973
23. Jinushi M, Takehara T, Tatsumi T, Kanto T, Miyagi T, Suzuki T, Kanazawa Y, Hiramatsu N, Hayashi N. Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection. J Immunol 2004; 173: 6072-6081
24. Sun R, Gao B. Negative regulation of liver regeneration by innate immunity (natural killer cells/interferon-gamma). Gastroenterology 2004; 127: 1525-1539
25. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 2000; 192: 921-930
26. Echevarria S, Casafont F, Miera M, Lozano JL, de la Cruz F, San Miguel G, Pons Romero F. Interleukin-2 and natural killer activity in acute type B hepatitis. Hepatogastroenterology 1991; 38: 307-310
27. Chemello L, Mondelli M, Bortolotti F, Schiavon E, Pontisso P, Alberti A, Rondanelli EG, Realdi G. Natural killer activity in patients with acute viral hepatitis. Clin Exp Immunol 1986; 64: 59-64
28. Lehoux M, Jacques A, Lusignan S, Lamontagne L. Murine viral hepatitis involves NK cell depletion associated with virus-induced apoptosis. Clin Exp Immunol 2004; 137: 41-51
29. Li Y, Zhang T, Ho C, Orange JS, Douglas SD, Ho WZ. Natural killer cells inhibit hepatitis C virus expression. J Leukoc Biol 2004; 76: 1171-1179
30. Bozkaya H, Bozdayi M, Turkyilmaz R, Sarioglu M, Cetinkaya H, Cinar K, Kose K, Yurdaydin C, Uzunalimoglu O. Circulating IL-2, IL-10 and TNF-alpha in chronic hepatitis B: their relations to HBeAg status and the activity of liver disease. Hepatogastroenterology 2000; 47: 1675-1679
31. Monsalve-De Castillo F, Romero TA, Estevez J, Costa LL, Atencio R, Porto L, Callejas D. Concentrations of cytokines, soluble interleukin-2 receptor, and soluble CD30 in sera of patients with hepatitis B virus infection during acute and convalescent phases. Clin Diagn Lab Immunol 2002; 9: 1372-1375
32. Tanaka Y, Takahashi A, Watanabe K, Takayama K, Yahata T, Habu S, Nishimura T. A pivotal role of IL-12 in Th1-dependent mouse liver injury. Int Immunol 1996; 8: 569-576
33. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001; 19: 65-91
34. Mahe Y, Mukaida N, Kuno K, Akiyama M, Ikeda N, Matsushima K, Murakami S. Hepatitis B virus X protein transactivates human interleukin-8 gene through acting on nuclear factor kB and CCAAT/enhancer-binding protein-like cis-elements. J Biol Chem 1991; 266: 13759-13763
35. Masumoto T, Ohkubo K, Yamamoto K, Ninomiya T, Abe M, Akbar SM, Michitaka K, Horiike N, Onji M. Serum IL-8 levels and localization of IL-8 in liver from patients with chronic viral hepatitis. Hepatogastroenterology 1998; 45: 1630-1634
36. Nobili V, Marcellini M, Giovannelli L, Girolami E, Muratori F, Giannone G, Devito R, De Benedetti F. Association of serum interleukin-8 levels with the degree of fibrosis in infants with chronic liver disease. J Pediatr Gastroenterol Nutr 2004; 39: 540-544
37. Sawayama Y, Hayashi J, Kawakami Y, Furusyo N, Ariyama I, Kishihara Y, Ueno K, Kashiwagi S. Serum soluble interleukin-2 receptor levels before and during interferon treatment in patients with chronic hepatitis B virus infection. Dig Dis Sci 1999; 44: 163-169
38. Xuan SY, Sun Y, Zhang J. The influence to the function of cellular immunity after being infected by HBV in the PBMC in chronic hepatitis B. Zhonghua Liuxing Bingxue Zazhi 1997; 18: 80-82